TITLE

Early detection of cytomegalovirus-specific cytotoxic T lymphocytes against cytomegalovirus antigenemia in human leukocyte antigen haploidentical hematopoietic stem cell transplantation

AUTHOR(S)
Kato, Ruri; Tamaki, Hiroya; Ikegame, Kazuhiro; Yoshihara, Satoshi; Kaida, Katsuji; Taniguchi, Kyoko; Inoue, Takayuki; Ishii, Shinichi; Nakata, Jun; Fujioka, Tatsuya; Eguchi, Ryoji; Soma, Toshihiro; Okada, Masaya; Ogawa, Hiroyasu
PUB. DATE
October 2015
SOURCE
Annals of Hematology;Oct2015, Vol. 94 Issue 10, p1707
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Human leukocyte antigen (HLA)-haploidentical stem cell transplantation (haplo-SCT) is associated with a high incidence of cytomegalovirus (CMV) infection, probably originating from the delayed reconstitution of CMV-specific T cell immunity. There have been few reports on the presence of CMV-specific cytotoxic T lymphocytes (CMV-CTLs) after haplo-SCT. We have studied CMV-specific immune reconstitution by measuring the absolute number of CMV-CTLs using a flow cytometry method with HLA-A2-restricted NLVPMVATV peptide dextramers. We examined the association between reconstitution patterns of CMV-CTLs and the duration of CMV antigenemia in 15 patients who underwent first allogeneic SCT from HLA-haploidentical-related donors with HLA-A2. In seven and eight patients, CMV antigenemia consecutively resolved for more than 4 weeks (the CMV antigenemia 'resolved' group) and intermittently persisted (the CMV antigenemia 'persistent' group) during a 100-day observation period, respectively. The group of the seven patients, in whom levels of CMV antigenemia were reduced to zero, had a significantly lower maximum level of CMV antigenemia than the CMV antigenemia persistent group. In contrast, the CMV antigenemia persistent group had a significantly higher maximum level of CMV-CTLs, but the levels took longer to peak. Despite no difference in general lymphocyte recovery between the two groups, the CMV antigenemia resolved group had significantly higher median CMV-CTL counts than the CMV antigenemia persistent group at 6 weeks after onset of CMV infection. Flow cytometry analysis of CMV-CTLs is a convenient method of monitoring reconstitution of CMV-specific lymphocyte immunity following haplo-SCT.
ACCESSION #
109250999

 

Related Articles

  • Signature profiles of CMV-specific T-cells in patients with CMV reactivation after hematopoietic SCT. Król, L.; Stuchlý, J.; Hubáček, P.; Keslová, P.; Sedláček, P.; Starý, J.; Hrušák, O.; Kalina, T. // Bone Marrow Transplantation;Aug2011, Vol. 46 Issue 8, p1089 

    Depletion of cellular immunity as a consequence of conditioning before allogeneic hematopoietic SCT (HSCT) frequently results in CMV reactivation, which may in turn lead to life-threatening infections and require timely antiviral treatment. We have investigated the functional signatures of...

  • Preface of the Special Issue: "Recent CMV Research". Dufrene, Kayla; DeBiasi, Roberta L.; Colberg-Poley, Anamaris M. // Viruses (1999-4915);Jan2014, Vol. 6 Issue 1, p336 

    A preface to the issue is presented where a congenital cytomegalovirus infection patient discusses her struggles with the disease throughout her life and her willingness to learn more about its symptoms, diagnosis, and treatment.

  • Reduced Mortality of Cytomegalovirus Pneumonia After Hematopoietic Cell Transplantation Due to Antiviral Therapy and Changes in Transplantation Practices. Erard, Veronique; Guthrie, Katherine A.; Sachiko Seo; Smith, Jeremy; MeeiLi Huang; Jason Chien; Flowers, Mary E. D.; Corey, Lawrence; Boeckh, Michael // Clinical Infectious Diseases;7/1/2015, Vol. 61 Issue 1, p31 

    Background. Despite major advances in the prevention of cytomegalovirus (CMV) disease, the treatment of CMV pneumonia in recipients of hematopoietic cell transplant remains a significant challenge. Methods. We examined recipient, donor, transplant, viral, and treatment factors associated with...

  • Foscarnet.  // Reactions Weekly;May2014, Vol. 1500 Issue 1, p19 

    An abstract of the article "UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease," by K. Gregg and colleagues is presented.

  • Ganciclovir.  // Reactions Weekly;Jun2015, Vol. 1554 Issue 1, p94 

    An abstract of the article "Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping," by E. Drouot is presented.

  • Intrathecal Administration of High-Titer Cytomegalovirus Immunoglobulin for Cytomegalovirus Meningitis. Shin-ichiro Fujiwara; Kazuo Muroi; Raine Tatara; Ken Ohmine; Tomohiro Matsuyama; Masaki Mori; Tadashi Nagai; Keiya Ozawa // Case Reports in Hematology;2014, p1 

    Cytomegalovirus (CMV) central nervous system disease after hematopoietic stem cell transplantation (HSCT) is a rare but life-threatening complication. Here, we report a patient who developed CMV meningitis after HSCT and was treated with the combination therapy of intrathecal high-titer CMV...

  • Clostridium Cadaveris Splenic Abscess in an Adolescent. Yan, Jennifer; Hinds, Rupert; Burgner, David // Journal of Paediatrics & Child Health;Apr2018, Vol. 54 Issue 4, p460 

    No abstract available.

  • Congenital Cytomegalovirus Infection Presenting with Isolated Secretory Diarrhoea Mimicking a Congenital Diarrhoeal Disorder. Osatakul, Seksit; Chanpong, Atchariya; Pruekprasert, Pornpimol // Journal of Paediatrics & Child Health;Apr2018, Vol. 54 Issue 4, p460 

    No abstract available.

  • Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Saito, A. M.; Zahrieh, D.; Cutler, C.; Ho, V. T.; Antin, J. H.; Soiffer, R. J.; Alyea, E. P.; Lee, S. J. // Bone Marrow Transplantation;Aug2007, Vol. 40 Issue 3, p209 

    We compared inpatient and outpatient costs alongside clinical outcomes associated with hematopoietic cell transplantation between 2000 and 2003 with high-dose regimens (HDCT, n=185) and with reduced intensity regimens (RICT, n=90) from human leukocyte antigen (HLA)-matched donors for patients...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics